67 reports of this reaction
1.6% of all NORETHINDRONE ACETATE reports
#20 most reported adverse reaction
BREAST CANCER is the #20 most commonly reported adverse reaction for NORETHINDRONE ACETATE. There are 67 FDA adverse event reports linking NORETHINDRONE ACETATE to BREAST CANCER. This represents approximately 1.6% of all 4,107 adverse event reports for this drug.
Patients taking NORETHINDRONE ACETATE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a less commonly reported adverse event for NORETHINDRONE ACETATE, but still significant enough to appear in the safety profile.
In addition to breast cancer, the following adverse reactions have been reported for NORETHINDRONE ACETATE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 67 FDA reports for NORETHINDRONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 1.6% of all adverse event reports for NORETHINDRONE ACETATE, making it a notable side effect.
If you experience breast cancer while taking NORETHINDRONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.